SPIA
CLVS

Steward Partners Investment Advisory’s Clovis Oncology, Inc. CLVS Stock Holding History

Steward Partners Investment Advisory’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,500
Closed -$17.6K – 7524
2021
Q1 		$17.6K Buy
+2,500
New +$16.8K ﹤0.01% 2539
2020
Q4 		– Sell
-1,000
Closed -$6K – 3034
2020
Q3 		$6K Hold
1,000
– – ﹤0.01% 2331
2020
Q2 		$7K Buy
+1,000
New +$7.57K ﹤0.01% 2193

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Steward Partners Investment Advisory's CLVS Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of Clovis Oncology, Inc. (CLVS) in Q2 2021, closing a stake of 2,500 shares — an estimated $17.6K sold.

Steward Partners Investment Advisory first reported a position in CLVS in Q2 2020 and held it in 3 quarters. The position peaked at $17.6K in Q1 2021. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

  • Steward Partners Investment Advisory reported no remaining Clovis Oncology, Inc. position as of Q2 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 2,500 Clovis Oncology, Inc. shares in Q2 2021, an estimated $17.6K.
  • Steward Partners Investment Advisory first reported a position in Clovis Oncology, Inc. in Q2 2020 and held it in 3 quarters.
  • Steward Partners Investment Advisory's Clovis Oncology, Inc. position peaked at $17.6K in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.